Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide
@article{Loria2008StudyOT, title={Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide}, author={Frida Loria and Stefania Petrosino and Leyre Mestre and Alessandra Spagnolo and Fernando G Correa and M{\'i}riam Hernang{\'o}mez and Carmen Guaza and Vincenzo Di Marzo and Fabian Docagne}, journal={European Journal of Neuroscience}, year={2008}, volume={28} }
Cannabinoids have recently been approved as a treatment for pain in multiple sclerosis (MS). Increasing evidence from animal studies suggests that this class of compounds could also prove efficient to fight neurodegeneration, demyelination, inflammation and autoimmune processes occurring in this pathology. However, the use of cannabinoids is limited by their psychoactive effects. In this context, potentiation of the endogenous cannabinoid signalling could represent a substitute to the use of…
105 Citations
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice
- BiologyNeuroscience
- 2015
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
- Biology, MedicineProgress in Neurobiology
- 2018
Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease
- Biology, MedicineInternational reviews of immunology
- 2015
It is proposed that the peripheral CB1 receptor is involved in the regulation and amelioration of inflammation associated with autoimmune diseases.
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination
- BiologyBiochemical pharmacology
- 2018
An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis
- Biology, ChemistryNeurobiology of Disease
- 2010
Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?
- BiologyExperimental Neurology
- 2010
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroin fl ammatory diseases
- Biology, Medicine
- 2017
The preclinical and clinical studies that could explain the therapeutic action of cannabinoid-based medicines, as well as the medical potential of modulating endocannabinoid signaling in multiple sclerosis, with a link to other neuroinflammatory disorders that share common hallmarks and pathogenetic features are reviewed.
The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease
- BiologyAmino Acids
- 2012
Current information on immune effects of cannabinoids in health and disease is outlined and it is shown that the endocannabinoid system represents a revolving plate of neural and immune interactions.
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
- BiologyFrontiers in Cellular Neuroscience
- 2020
This mini review article summarizes what is currently known about the peripheral and central effects of cannabinoids in relation to the neuroinflammation coupled to MS, with special attention to their effects on remyelination and axon preservation within the CNS.
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
- Biology, PsychologyFrontiers in Psychiatry
- 2022
Its non-psychoactive effect makes theCB2R a potential target for treating CNS disorders; however, a better understanding of the fundamental pharmacology of CB2R activation is essential for the design of novel therapeutic strategies.
References
SHOWING 1-10 OF 52 REFERENCES
Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis
- Biology, MedicineFASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2005
The results indicate that treatment during established disease significantly improves the motor function of the diseased mice and suggest that agents able to activate the endocannabinoid system could constitute a new series of drugs for the treatment of MS.
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
- BiologyNeurobiology of Disease
- 2005
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis
- BiologyJournal of neurochemistry
- 2005
OMDM1 and OMDM2 provide an effective therapy for Theiler murine encephalomyelitis virus‐induced demyelinating disease (TMEV‐IDD) and point to the manipulation of the endocannabinoid system as a possible strategy to develop future MS therapeutic drugs.
The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
- Biology, PsychologyInternational review of neurobiology
- 2007
Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.
- Biology, MedicinePharmacological research
- 2007
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation
- BiologyMolecular and Cellular Neuroscience
- 2007
Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis
- Biology, MedicineThe Journal of Neuroscience
- 2007
As seen for other neuroinflammatory conditions, selective glial expression of cannabinoid CB1 and CB2 receptors and FAAH enzyme is induced in MS, thus supporting a role for the endocannabinoid system in the pathogenesis and/or evolution of this disease.
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.
- Biology, MedicineThe Journal of biological chemistry
- 2008
Evidence for a new site of CB(2) receptor action, namely the targeting of myeloid progenitor trafficking and its contribution to microglial activation, is provided and the potential use of non-psychoactive CB( 2) agonists in therapeutic strategies for multiple sclerosis and other neuroinflammatory disorders is supported.
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease
- BiologyNeurochemistry International
- 2008
Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders
- Biology, PsychologyNature Clinical Practice Neurology
- 2007
The finding that activation of peroxisome proliferator-activated receptor-γ (PPARγ) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the…